Deltagen Inc. reported unaudited consolidated financial results for the first quarter ended March 31, 2013. The company's consolidated revenues for the three months ended March 31, 2013 totaled $0.194 million. The revenues in the first quarter of 2013 were attributable primarily to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the Company's DeltaOne(TM) program.

The consolidated revenues for the period included $0.040 million for Xenopharm Inc. Consolidated net losses before provision for income taxes for the three months ended March 31, 2013 were $0.541 million, which included a net loss of $0.063 million from operations and a recognized net loss of $0.478 million from investments made by the Company in Benten BioServices Inc., which was accounted for using the Equity Method of Accounting. Income from operations was $63,000. loss before provision for income taxes and net loss was $604,000.